Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy

Soo Hyun Kim, Do Hwan Seong, Sang Min Yoon, Young Deuk Choi, Eunju Choi, Hosook Song

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose We aimed to examine the level of psychological distress, fatigue, and health-related quality of life (HRQOL) and identify HRQOL predictors in men with prostate cancer receiving androgen deprivation therapy (ADT). Methods Using a cross-sectional design, we recruited 161 men with prostate cancer receiving ADT (mean age, 73 years) at two university-based hospitals in South Korea. Participants completed a self-reported questionnaire. Measures included the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale, and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Results The mean scores were 3.3 (SD = 2.8) for anxiety with a prevalence of 8.9%, 5.7 (SD = 3.8) for depression with a prevalence of 25.5%, and 30.3 (SD = 7.4) for fatigue with a prevalence of 15.6%. The five FACT-P subscale means were 23.9 (SD = 4.3) for physical well-being, 15.4 (SD = 6.4) for social well-being, 18.5 (SD = 4.3) for emotional well-being, 17.3 (SD = 5.6) for functional well-being, and 30.3 (SD = 7.4) for the prostate cancer-specific subscale. Multiple linear regression analysis revealed that depression, which was inversely associated with all FACT-P subscales, was the strongest predictor of worse HRQOL. Fatigue and comorbid conditions were also associated with the HRQOL of multiple domains. Conclusion This study suggests that intervention aimed at improving HRQOL of men receiving ADT should include depression, fatigue, and comorbidity management.

Original languageEnglish
Pages (from-to)84-90
Number of pages7
JournalEuropean Journal of Oncology Nursing
Volume30
DOIs
Publication statusPublished - 2017 Oct

Fingerprint

Androgens
Prostatic Neoplasms
Quality of Life
Fatigue
Depression
Therapeutics
Anxiety
Republic of Korea
Comorbidity
Linear Models
Chronic Disease
Regression Analysis
Psychology

All Science Journal Classification (ASJC) codes

  • Oncology(nursing)

Cite this

@article{78445aae556f4f73b20e774d74731523,
title = "Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy",
abstract = "Purpose We aimed to examine the level of psychological distress, fatigue, and health-related quality of life (HRQOL) and identify HRQOL predictors in men with prostate cancer receiving androgen deprivation therapy (ADT). Methods Using a cross-sectional design, we recruited 161 men with prostate cancer receiving ADT (mean age, 73 years) at two university-based hospitals in South Korea. Participants completed a self-reported questionnaire. Measures included the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale, and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Results The mean scores were 3.3 (SD = 2.8) for anxiety with a prevalence of 8.9{\%}, 5.7 (SD = 3.8) for depression with a prevalence of 25.5{\%}, and 30.3 (SD = 7.4) for fatigue with a prevalence of 15.6{\%}. The five FACT-P subscale means were 23.9 (SD = 4.3) for physical well-being, 15.4 (SD = 6.4) for social well-being, 18.5 (SD = 4.3) for emotional well-being, 17.3 (SD = 5.6) for functional well-being, and 30.3 (SD = 7.4) for the prostate cancer-specific subscale. Multiple linear regression analysis revealed that depression, which was inversely associated with all FACT-P subscales, was the strongest predictor of worse HRQOL. Fatigue and comorbid conditions were also associated with the HRQOL of multiple domains. Conclusion This study suggests that intervention aimed at improving HRQOL of men receiving ADT should include depression, fatigue, and comorbidity management.",
author = "Kim, {Soo Hyun} and Seong, {Do Hwan} and Yoon, {Sang Min} and Choi, {Young Deuk} and Eunju Choi and Hosook Song",
year = "2017",
month = "10",
doi = "10.1016/j.ejon.2017.08.009",
language = "English",
volume = "30",
pages = "84--90",
journal = "European Journal of Oncology Nursing",
issn = "1462-3889",
publisher = "Churchill Livingstone",

}

Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy. / Kim, Soo Hyun; Seong, Do Hwan; Yoon, Sang Min; Choi, Young Deuk; Choi, Eunju; Song, Hosook.

In: European Journal of Oncology Nursing, Vol. 30, 10.2017, p. 84-90.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy

AU - Kim, Soo Hyun

AU - Seong, Do Hwan

AU - Yoon, Sang Min

AU - Choi, Young Deuk

AU - Choi, Eunju

AU - Song, Hosook

PY - 2017/10

Y1 - 2017/10

N2 - Purpose We aimed to examine the level of psychological distress, fatigue, and health-related quality of life (HRQOL) and identify HRQOL predictors in men with prostate cancer receiving androgen deprivation therapy (ADT). Methods Using a cross-sectional design, we recruited 161 men with prostate cancer receiving ADT (mean age, 73 years) at two university-based hospitals in South Korea. Participants completed a self-reported questionnaire. Measures included the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale, and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Results The mean scores were 3.3 (SD = 2.8) for anxiety with a prevalence of 8.9%, 5.7 (SD = 3.8) for depression with a prevalence of 25.5%, and 30.3 (SD = 7.4) for fatigue with a prevalence of 15.6%. The five FACT-P subscale means were 23.9 (SD = 4.3) for physical well-being, 15.4 (SD = 6.4) for social well-being, 18.5 (SD = 4.3) for emotional well-being, 17.3 (SD = 5.6) for functional well-being, and 30.3 (SD = 7.4) for the prostate cancer-specific subscale. Multiple linear regression analysis revealed that depression, which was inversely associated with all FACT-P subscales, was the strongest predictor of worse HRQOL. Fatigue and comorbid conditions were also associated with the HRQOL of multiple domains. Conclusion This study suggests that intervention aimed at improving HRQOL of men receiving ADT should include depression, fatigue, and comorbidity management.

AB - Purpose We aimed to examine the level of psychological distress, fatigue, and health-related quality of life (HRQOL) and identify HRQOL predictors in men with prostate cancer receiving androgen deprivation therapy (ADT). Methods Using a cross-sectional design, we recruited 161 men with prostate cancer receiving ADT (mean age, 73 years) at two university-based hospitals in South Korea. Participants completed a self-reported questionnaire. Measures included the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale, and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Results The mean scores were 3.3 (SD = 2.8) for anxiety with a prevalence of 8.9%, 5.7 (SD = 3.8) for depression with a prevalence of 25.5%, and 30.3 (SD = 7.4) for fatigue with a prevalence of 15.6%. The five FACT-P subscale means were 23.9 (SD = 4.3) for physical well-being, 15.4 (SD = 6.4) for social well-being, 18.5 (SD = 4.3) for emotional well-being, 17.3 (SD = 5.6) for functional well-being, and 30.3 (SD = 7.4) for the prostate cancer-specific subscale. Multiple linear regression analysis revealed that depression, which was inversely associated with all FACT-P subscales, was the strongest predictor of worse HRQOL. Fatigue and comorbid conditions were also associated with the HRQOL of multiple domains. Conclusion This study suggests that intervention aimed at improving HRQOL of men receiving ADT should include depression, fatigue, and comorbidity management.

UR - http://www.scopus.com/inward/record.url?scp=85028689837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028689837&partnerID=8YFLogxK

U2 - 10.1016/j.ejon.2017.08.009

DO - 10.1016/j.ejon.2017.08.009

M3 - Article

C2 - 29031319

AN - SCOPUS:85028689837

VL - 30

SP - 84

EP - 90

JO - European Journal of Oncology Nursing

JF - European Journal of Oncology Nursing

SN - 1462-3889

ER -